Open an account

Protalix Biotherapeutics

PLX · NYSE American

$2.64+$0.08 (+3.13%)TodayMarket closed ·
Prev close $2.56

About PLX

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 226 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Employees
226
Headquarters
Hackensack, New Jersey
Listed
Sep 6, 2010
Sector
Health Care
Industry
Biotechnology
Website
protalix.com

PLX key statistics

Market cap
212.71M
Price-earnings ratio
11.13
Dividend yield
—
Average volume
910.83K
Volume
702.71K
Open price
$2.58
High today
$2.65
Low today
$2.58
52 Week high
$3.19
52 Week low
$1.65

Protalix Biotherapeutics (PLX) at a glance

As of Oct 20, 2026, Protalix Biotherapeutics (PLX) shares are priced at $2.64, giving the company a market cap of 212.71M and a price-to-earnings ratio of 11.13.

Today the stock has traded between $2.58 and $2.65. The current price is 2.4% above the day's low and 0.4% below its high.

Volume so far is 702.71K shares, below the average of 910.83K shares a day.

Over the past year Protalix Biotherapeutics has ranged from $1.65 to $3.19, and now sits 64% of the way up that range.

Protalix Biotherapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.05 per share against an estimate of -$0.0101.

The average analyst price target is $11.22, 325.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $11.22
Low
$10.10
Now
$2.64
High
$12.60

PLX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 966.9% on average.

  1. Q3 FY24: reported $0.03 per share against an estimate of $0.0404
  2. Q4 FY24: reported $0.09 per share against an estimate of $0.0707
  3. Q1 FY25: reported -$0.05 per share against an estimate of $0.0303
  4. Q2 FY25: reported $0.00 per share against an estimate of $0.0303
  5. Q3 FY25: reported $0.03 per share against an estimate of $0.0556
  6. Q4 FY25: reported -$0.07 per share against an estimate of $0.0051
  7. Q1 FY26: reported $0.22 per share against an estimate of -$0.0101
  8. Q2 FY26: reported $0.05 per share against an estimate of -$0.0101

PLX news

  • Press releasePRNewswire

    Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

  • Press releasePRNewswire

    Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

  • Press releasePRNewswire

    Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

  • Press releasePRNewswire

    Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

  • Press releasePRNewswire

    Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

  • Press releasePRNewswire

    Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

Similar companies

Companies in the same industry as Protalix Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.